Cargando…

The predictive value of total-body PET/CT in non-small cell lung cancer for the PD-L1 high expression

PURPOSE: Total-body positron emission tomography/computed tomography (PET/CT) provides faster scanning speed, higher image quality, and lower injected dose. To compensate for the shortcomings of the maximum standard uptake value (SUVmax), we aimed to normalize the values of PET parameters using live...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Bingxin, Jin, Huibin, Li, Xiali, Wu, Xinyu, Xu, Junling, Gao, Yongju
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9538674/ https://www.ncbi.nlm.nih.gov/pubmed/36212409 http://dx.doi.org/10.3389/fonc.2022.943933

Ejemplares similares

Diagnostic accuracy of (99m)Tc-HYNIC-TOC SPECT/CT for detecting osteomalacia-associated tumors
por: Li, Bo, et al.
Publicado: (2023)

Evaluation of PD-L1 Expression Level in Patients With Non-Small Cell Lung Cancer by (18)F-FDG PET/CT Radiomics and Clinicopathological Characteristics
por: Li, Jihui, et al.
Publicado: (2021)

Prognostic Value of Heterogeneity Index Derived from Baseline (18)F-FDG PET/CT in Mantle Cell Lymphoma
por: Liu, Fei, et al.
Publicado: (2022)

Diagnostic Value of Delayed PET/MR in Liver Metastasis in Comparison With PET/CT
por: Zhou, Nina, et al.
Publicado: (2021)

Additional Value of PET/CT-Based Radiomics to Metabolic Parameters in Diagnosing Lynch Syndrome and Predicting PD1 Expression in Endometrial Carcinoma
por: Wang, Xinghao, et al.
Publicado: (2021)

Recognizing Tumor Origin for Lymphoid Tumor of Unknown Primary via Total-Body PET/CT Scan—Case Report
por: Lu, Weizhao, et al.
Publicado: (2022)

Prognostic Value of the Pretreatment Lung Immune Prognostic Index in Advanced Small Cell Lung Cancer Patients Treated With First-Line PD-1/PD-L1 Inhibitors Plus Chemotherapy
por: Li, Lingling, et al.
Publicado: (2021)

Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer
por: Su, Chaoyue, et al.
Publicado: (2020)

The Place of FDG PET/CT in Renal Cell Carcinoma: Value and Limitations
por: Liu, Yiyan
Publicado: (2016)

Radiomics Study for Predicting the Expression of PD-L1 and Tumor Mutation Burden in Non-Small Cell Lung Cancer Based on CT Images and Clinicopathological Features
por: Wen, Qiang, et al.
Publicado: (2021)

Predictive value of baseline metabolic tumor burden on (18)F-FDG PET/CT for brain metastases in patients with locally advanced non-small-cell lung cancer
por: Shang, Jingjie, et al.
Publicado: (2022)

Diagnostic Value of (18)F-NOTA-FAPI PET/CT in a Rat Model of Radiation-Induced Lung Damage
por: Qin, Xueting, et al.
Publicado: (2022)

The value of combined PET/MRI, CT and clinical metabolic parameters in differentiating lung adenocarcinoma from squamous cell carcinoma
por: Tang, Xin, et al.
Publicado: (2022)

Harmonization of Molecular Testing for Non-Small Cell Lung Cancer: Emphasis on PD-L1
por: Imyanitov, Evgeny N., et al.
Publicado: (2020)

Relationship between standardized uptake value on 18F-FDG PET and PD-L1 expression in clear cell renal cell carcinoma
por: Liu, Ying, et al.
Publicado: (2022)

Value of preoperative (18)F-FDG PET/CT and HRCT in predicting the differentiation degree of lung adenocarcinoma dominated by solid density
por: Chen, Xiaolin, et al.
Publicado: (2023)

The combined role of PET/CT metabolic parameters and inflammatory markers in detecting extensive disease in small cell lung cancer
por: Hu, Yao, et al.
Publicado: (2022)

The Predictive Value of Pretreatment Lactate Dehydrogenase and Derived Neutrophil-to-Lymphocyte Ratio in Advanced Non-Small Cell Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors: A Meta-Analysis
por: Zhang, Qianning, et al.
Publicado: (2022)

Efficacy and Safety of PD-1/PD-L1 Inhibitors Plus Chemotherapy Versus PD-1/PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer: A Network Analysis of Randomized Controlled Trials
por: Li, Xiang, et al.
Publicado: (2021)

Early Phase I Study of a (99m)Tc-Labeled Anti–Programmed Death Ligand-1 (PD-L1) Single-Domain Antibody in SPECT/CT Assessment of PD-L1 Expression in Non–Small Cell Lung Cancer
por: Xing, Yan, et al.
Publicado: (2019)

A deep learning approach for automatic tumor delineation in stereotactic radiotherapy for non-small cell lung cancer using diagnostic PET-CT and planning CT
por: Yu, Xuyao, et al.
Publicado: (2023)

Prognostic values of ALDOB expression and (18)F-FDG PET/CT in hepatocellular carcinoma
por: Jia, Wenzhi, et al.
Publicado: (2022)

Clinical value of (18)F-FDG PET/CT in the management of HIV-associated lymphoma
por: Liu, Qi, et al.
Publicado: (2023)

First-in-Humans Evaluation of a PD-L1–Binding Peptide PET Radiotracer in Non–Small Cell Lung Cancer Patients
por: Zhou, Xin, et al.
Publicado: (2022)

Prognostic value of (18)F-FDG PET/CT radiomic model based on primary tumor in patients with non-small cell lung cancer: A large single-center cohort study
por: Li, Jihui, et al.
Publicado: (2022)

Immune checkpoint inhibitors for PD-1/PD-L1 axis in combination with other immunotherapies and targeted therapies for non-small cell lung cancer
por: Mussafi, Ofek, et al.
Publicado: (2022)

PET/CT Imaging of Activated Cancer-Associated Fibroblasts Predict Response to PD-1 Blockade in Gastric Cancer Patients
por: Rong, Xiaoxiang, et al.
Publicado: (2022)

Prediction of 5-year progression-free survival in advanced nasopharyngeal carcinoma with pretreatment PET/CT using multi-modality deep learning-based radiomics
por: Gu, Bingxin, et al.
Publicado: (2022)

Diagnosing small bowel carcinoid tumor in a patient with oligometastatic prostate cancer imaged with PSMA-Targeted [(18)F]DCFPyL PET/CT: Value of the PSMA-RADS-3D Designation
por: Shenderov, Eugene, et al.
Publicado: (2017)

Self-supervised contrastive learning using CT images for PD-1/PD-L1 expression prediction in hepatocellular carcinoma
por: Xie, Tianshu, et al.
Publicado: (2023)

Performance of (18)F-FDG PET/CT Radiomics for Predicting EGFR Mutation Status in Patients With Non-Small Cell Lung Cancer
por: Zhang, Min, et al.
Publicado: (2020)

(18)F-FDG PET/CT radiomics nomogram for predicting occult lymph node metastasis of non-small cell lung cancer
por: Qiao, Jianyi, et al.
Publicado: (2022)

(18)F-FDG PET/CT radiomics for prediction of lymphovascular invasion in patients with early stage non-small cell lung cancer
por: Wang, Jie, et al.
Publicado: (2023)

Clinical utility of texture analysis of 18F-FDG PET/CT in patients with Stage I lung cancer treated with stereotactic body radiotherapy
por: Takeda, Kazuya, et al.
Publicado: (2017)

(18)F-DCFPyL PET/CT in Newly Diagnosed Prostate Cancer: Diagnostic Value of Intraprostatic PSMA Uptake in Risk Classification of Prostate Cancer
por: Zhou, Shuoming, et al.
Publicado: (2022)

Corrigendum: PET/Ct Imaging of Activated Cancer-Associated Fibroblasts Predict Response to PD-1 Blockade in Gastric Cancer Patients
por: Rong, Xiaoxiang, et al.
Publicado: (2022)

A Novel Validated Recurrence Stratification System Based on (18)F-FDG PET/CT Radiomics to Guide Surveillance After Resection of Pancreatic Cancer
por: Wei, Miaoyan, et al.
Publicado: (2021)

4D PET/CT as a Strategy to Reduce Respiratory Motion Artifacts in FDG-PET/CT
por: Chi, Alexander, et al.
Publicado: (2014)

Clinical Outcomes for PD-1 Inhibitor Plus Chemotherapy as Second-Line or Later Therapy Compared to PD-1/PD-L1 Inhibitor Alone in Advanced Non-small-cell Lung Cancer
por: Zhai, Xiaoyang, et al.
Publicado: (2020)

Value of (18)F-FDG PET/MRI in the Preoperative Assessment of Resectable Esophageal Squamous Cell Carcinoma: A Comparison With (18)F-FDG PET/CT, MRI, and Contrast-Enhanced CT
por: Wang, Fei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_75m8k88m8qrdtudfabkuideqvt